We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Medipan to Distribute Pronostics' Autoimmune Diagnostics in Germany and Austria

By HospiMedica staff writers
Posted on 17 Mar 2008
Print article
Pronostics Ltd. (Cambridge, UK), a developer and manufacturer of next-generation multiplexed diagnostics, has signed a distribution agreement with Medipan GmbH (Berlin, Germany) for its autoimmune disease biomarker assays. Medipan, which distributes in vitro diagnostic tests in the field of autoimmunity, will have an exclusive license to sell Pronostics' UltraPlex ANA, coeliac, and thyroid assays in Germany and Austria.

Germany is Europe's largest market for diagnostic products. As part of the agreement, Medipan will market the assays to hospitals and large private laboratories. The deal could initially generate up to US$3.1 million (€2 million) in revenues.

UltraPlex assays provide a powerful tool for rapid, accurate, and inexpensive diagnosis of autoimmune diseases. UltraPlex is a highly accurate, digital multiplexing solution that enables tens to hundreds of tests to be performed simultaneously in a single assay using a microscopic bar-coding system. Pronostics lead product, the UltraPlex ANA assay, which consists of 11 tests in one, provides valuable time and cost savings compared to existing serial testing approaches using panels of human epithelial type 2 cell (Hep-2) screens and enzyme-linked immunosorbant assays (ELISAs). It allows hospitals and laboratories to perform fully automated profiles of patient samples and gives both quantitative and qualitative results for antibodies to autoimmune diseases.

Dr Dirk Roggenbuck, CEO of Medipan, said: "We are very pleased to have been chosen as the distributor for the UltraPlex range of autoimmune assays. The UltraPlex platform is more efficient and economical in the diagnosis of autoimmune diseases than conventional approaches, and we are looking forward to providing our customers with this improved service.”

Medipan develops and distributes in-vitro diagnostic tests, predominantly in the field of autoimmunity. Medipan's product portfolio provides a wide range of assays and it is expanding continuously. The company offers technical, medical, and scientific expertise and support ensuring the success of their partner's clinical and business objectives.


Related Links:
Pronostics
Medipan
Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Thyroxine ELISA
T4 ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.